Navigation Links
Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.

VANCOUVER, Canada, Aug. 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

XEN402 has been developed by Xenon as a topical ointment formulation and recently concluded a 21-day cumulative dose safety tolerability phase 1 study in normal human volunteers.  The product was well tolerated and achieved good drug concentrations in the skin.  Topical XEN402 is being developed by Xenon for painful neuropathic disorders such as PHN and targets the sodium channel sub-type Nav1.7. This target is highly expressed in sensory nerve endings and its expression has been shown to be up-regulated in chronic painful conditions such as PHN.

"This is an important step forward in the development of topical XEN402," said Xenon President & CEO, Dr. Simon Pimstone.  "This is a truly unique product built on our genetic studies that showed Nav1.7 deficient humans are completely unable to feel pain. By treating pain locally at its source through Nav1.7 block, topical XEN402 could be a very effective and safe treatment option. Our pre-clinical data show excellent efficacy with topical XEN402 in multiple inflammatory and neuropathic pain models when compared to other topical agents and additive effects to existing oral pain treatments.  We are excited by these findings as the product could eventually treat multiple chronic painful conditions.  This progress signifies another example of Xenon transitioning its target discovery engine to human proof-of-concept trials."

Xenon's VP, Clinical Development, Dr. Paul Goldberg referred to topical XEN402 as a "potentially transformative therapy as leading agents have significant side effects and often leave many patients still in pain.  As such there is a large unmet medical need for a novel analgesic that is both effective and safe. We see topical XEN402 being used both as a monotherapy and as an adjuvant agent as well," he added.

Xenon expects to conclude the phase 2 trial in Q1, 2011 with top-line data available in Q2, 2011.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
2. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
3. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
4. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
9. Angiotech Pharmaceuticals Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  Twist Bioscience, a ... Emily Leproust , Ph.D., has been selected as one ... 2015 for fast-tracking the building blocks of life . ... Global Thinkers whose contributions and work have changed lives ... --> "It is an honor to be recognized ...
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015 /PRNewswire/ ... that uses allogeneic stem cells for cardiovascular indications, ... clinical trial protocol based on recommendations from a ... leaders and its Scientific Advisory Board members ... boards analyzed preliminary Phase IIa safety and efficacy ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global ... practitioners and aesthetics professionals from Central America and abroad for the first Iberoamerican ... City, Panama Feb. 17-19, 2016. Testart will present and discuss new trends in ...
Breaking Biology Technology:
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):